ANIP ANI PHARMACEUTICALS INC
Nasdaq · SEC CIK 1023024 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $14.87M 41 sales by 12 insiders
- Filings on record
- 320 since 2021-09-10, latest 2026-09-16 16:20
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lalwani Nikhil | Pres, CEO, Dir | — | $5.05M |
| Walsh Patrick D | Dir | — | $2.32M |
| CAREY STEPHEN P. | SVP, CFO | — | $1.78M |
| Mutz Christopher | HEAD OF RARE DISEASE | — | $1.64M |
| Gassert Chad | SVP - CORP. DEV, STRATEGY | — | $1.31M |
| Davis Krista | SVP, Chief HR Off | — | $918.6K |
| Gutwerg Ori | SVP, GENERICS | — | $621.4K |
| Cook Meredith | SVP, GC, SEC | — | $453.9K |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | — | $393.8K |
| HAUGHEY THOMAS | Dir | — | $161.8K |
Transactions 356
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-18 | 2025-08-15 | ANIP | Walsh Patrick D | Dir | S - Sale | $89.05 | -9,000 | 70.0K | -11% | -$801.5K | |
| I | 2025-08-18 | 2025-08-15 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $86.97 | -20.0K | 173.2K | -10% | -$1.74M |
| 2025-08-18 | 2025-08-18 | ANIP | Leonard Matthew J | Dir | S - Sale | $88.17 | -6,937 | 9,392 | -42% | -$611.6K | |
| 2025-08-14 | 2025-08-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $88.87 | -400 | 76.5K | -0.5% | -$35.5K | |
| 2025-08-14 | 2025-08-12 | ANIP | Gutwerg Ori | SVP, GENERICS | S - Sale | $86.53 | -5,873 | 84.0K | -7% | -$508.2K | |
| 2025-08-14 | 2025-08-12 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | S - Sale | $85.71 | -4,975 | 40.8K | -11% | -$426.4K | |
| 2025-08-14 | 2025-08-12 | ANIP | HAUGHEY THOMAS | Dir | S - Sale | $85.93 | -19.3K | 36.5K | -35% | -$1.66M | |
| 2025-08-14 | 2025-08-12 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale | $85.93 | -57.0K | 411.2K | -12% | -$4.89M | |
| D | 2025-08-14 | 2025-08-12 | ANIP | CAREY STEPHEN P. | SVP, CFO | M - OptEx | $46.49 | +50.0K | 230.9K | +28% | +$2.32M |
| D | 2025-08-14 | 2025-08-12 | ANIP | CAREY STEPHEN P. | SVP, CFO | S - Sale+OE | $86.07 | -50.0K | 180.9K | -22% | -$4.30M |
| 2025-07-21 | 2025-07-18 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $66.30 | -2,071 | 76.9K | -3% | -$137.3K | |
| 2025-07-14 | 2025-07-14 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $64.88 | -400 | 78.9K | -0.5% | -$26.0K | |
| 2025-06-16 | 2025-06-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $61.37 | -400 | 79.3K | -0.5% | -$24.5K | |
| 2025-05-27 | 2025-05-22 | ANIP | Pera Antonio R | Dir | A - Grant | $0.00 | +4,336 | 35.4K | +14% | $0 | |
| 2025-05-27 | 2025-05-22 | ANIP | TANNENBAUM RENEE P | Dir | A - Grant | $0.00 | +4,336 | 27.0K | +19% | $0 | |
| 2025-05-27 | 2025-05-22 | ANIP | Thoma Jeanne | Dir | A - Grant | $0.00 | +4,336 | 44.9K | +11% | $0 | |
| 2025-05-27 | 2025-05-22 | ANIP | Leonard Matthew J | Dir | A - Grant | $0.00 | +4,336 | 16.3K | +36% | $0 | |
| 2025-05-27 | 2025-05-22 | ANIP | Walsh Patrick D | Dir | A - Grant | $0.00 | +4,336 | 79.0K | +6% | $0 | |
| 2025-05-27 | 2025-05-22 | ANIP | HAUGHEY THOMAS | Dir | A - Grant | $0.00 | +4,336 | 55.9K | +8% | $0 | |
| 2025-05-16 | 2025-05-15 | ANIP | Gutwerg Ori | SVP, GENERICS | S - Sale | $60.07 | -881 | 89.9K | -1.0% | -$52.9K | |
| 2025-05-15 | 2025-05-14 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $60.45 | -4,000 | 107.3K | -4% | -$241.8K | |
| I | 2025-05-13 | 2025-05-09 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $76.83 | -700 | 631.9K | -0.1% | -$53.8K |
| 2025-05-13 | 2025-05-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $62.20 | -400 | 79.7K | -0.5% | -$24.9K | |
| 2025-04-14 | 2025-04-14 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $68.96 | -400 | 80.1K | -0.5% | -$27.6K | |
| 2025-03-25 | 2025-03-23 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $64.26 | -6,210 | 180.9K | -3% | -$399.1K | |
| 2025-03-25 | 2025-03-23 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $64.26 | -17.5K | 468.2K | -4% | -$1.12M | |
| 2025-03-20 | 2025-03-19 | ANIP | Davis Krista | SVP, Chief HR Off | S - Sale | $65.00 | -1,866 | 64.7K | -3% | -$121.3K | |
| 2025-03-14 | 2025-03-07 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $60.62 | -3,314 | 90.8K | -4% | -$200.9K | |
| 2025-03-14 | 2025-03-07 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $60.62 | -5,150 | 187.1K | -3% | -$312.2K | |
| 2025-03-14 | 2025-03-07 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $60.62 | -2,874 | 111.3K | -3% | -$174.2K | |
| 2025-03-14 | 2025-03-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $63.33 | -400 | 80.5K | -0.5% | -$25.3K | |
| 2025-03-14 | 2025-03-07 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $60.62 | -17.1K | 485.6K | -3% | -$1.03M | |
| 2025-03-10 | 2025-03-07 | ANIP | Davis Krista | SVP, Chief HR Off | S - Sale | $60.86 | -1,000 | 66.5K | -1% | -$60.9K | |
| D | 2025-03-07 | 2025-03-05 | ANIP | Gutwerg Ori | SVP, GENERICS | M - OptEx | $31.49 | +300 | 99.5K | +0.3% | +$9,447 |
| DM | 2025-03-07 | 2025-03-05 | ANIP | Gutwerg Ori | SVP, GENERICS | S - Sale+OE | $60.00 | -5,384 | 99.2K | -5% | -$323.0K |
| 2025-03-04 | 2025-02-28 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $61.89 | -12.2K | 502.7K | -2% | -$756.0K | |
| 2025-03-04 | 2025-02-28 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F - Tax | $61.89 | -627 | 45.5K | -1% | -$38.8K | |
| 2025-03-04 | 2025-02-28 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $61.89 | -1,861 | 192.2K | -1.0% | -$115.2K | |
| 2025-03-04 | 2025-02-28 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $61.89 | -1,099 | 80.9K | -1% | -$68.0K | |
| 2025-03-04 | 2025-02-28 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $61.89 | -1,275 | 114.2K | -1% | -$78.9K | |
| 2025-03-04 | 2025-02-28 | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $61.89 | -1,570 | 99.2K | -2% | -$97.2K | |
| 2025-03-04 | 2025-02-28 | ANIP | Davis Krista | SVP, Chief HR Off | F - Tax | $61.89 | -1,099 | 67.5K | -2% | -$68.0K | |
| 2025-02-24 | 2025-02-21 | ANIP | Davis Krista | SVP, Chief HR Off | S - Sale | $60.20 | -1,000 | 68.6K | -1% | -$60.2K | |
| M | 2025-02-18 | 2025-02-12 | ANIP | Davis Krista | SVP, Chief HR Off | A - Grant | $0.00 | +21.8K | 70.8K | +44% | $0 |
| 2025-02-18 | 2025-02-14 | ANIP | Davis Krista | SVP, Chief HR Off | F - Tax | $58.92 | -1,196 | 69.6K | -2% | -$70.5K | |
| M | 2025-02-18 | 2025-02-12 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | A - Grant | $0.00 | +23.9K | 92.6K | +35% | $0 |
| M | 2025-02-18 | 2025-02-12 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | A - Grant | $0.00 | +152.3K | 522.7K | +41% | $0 |
| 2025-02-18 | 2025-02-14 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $58.92 | -7,799 | 514.9K | -1% | -$459.5K | |
| M | 2025-02-18 | 2025-02-12 | ANIP | CAREY STEPHEN P. | SVP, CFO | A - Grant | $0.00 | +41.3K | 195.8K | +27% | $0 |
| 2025-02-18 | 2025-02-14 | ANIP | CAREY STEPHEN P. | SVP, CFO | F - Tax | $58.92 | -1,730 | 194.1K | -0.9% | -$101.9K | |
| M | 2025-02-18 | 2025-02-14+ | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | F - Tax | $58.92 | -2,657 | 116.7K | -2% | -$156.6K |
| M | 2025-02-18 | 2025-02-12 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | A - Grant | $0.00 | +41.3K | 118.1K | +54% | $0 |
| M | 2025-02-18 | 2025-02-14+ | ANIP | Gutwerg Ori | SVP, GENERICS | F - Tax | $58.92 | -2,593 | 101.9K | -2% | -$152.8K |
| M | 2025-02-18 | 2025-02-12 | ANIP | Gutwerg Ori | SVP, GENERICS | A - Grant | $0.00 | +26.1K | 103.3K | +34% | $0 |
| M | 2025-02-18 | 2025-02-12 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | A - Grant | $0.00 | +23.9K | 64.0K | +60% | $0 |
| M | 2025-02-18 | 2025-02-12 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | A - Grant | $0.00 | +13.1K | 41.5K | +46% | $0 |
| 2025-02-18 | 2025-02-14 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F - Tax | $58.92 | -582 | 46.1K | -1% | -$34.3K | |
| M | 2025-02-18 | 2025-02-12 | ANIP | Cook Meredith | SVP, GC, SEC | A - Grant | $0.00 | +28.3K | 83.9K | +51% | $0 |
| 2025-02-18 | 2025-02-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $59.54 | -400 | 83.5K | -0.5% | -$23.8K | |
| 2025-02-18 | 2025-02-14 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $58.92 | -1,434 | 82.0K | -2% | -$84.5K | |
| 2025-01-13 | 2025-01-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $53.92 | -400 | 55.6K | -0.7% | -$21.6K | |
| 2024-12-18 | 2024-12-17 | ANIP | CAREY STEPHEN P. | SVP, CFO | S - Sale | $55.79 | -7,500 | 154.5K | -5% | -$418.4K | |
| 2024-12-16 | 2024-12-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $56.24 | -250 | 56.0K | -0.4% | -$14.1K | |
| 2024-12-12 | 2024-12-11 | ANIP | Davis Krista | SVP, Chief HR Off | S - Sale | $60.00 | -1,000 | 49.1K | -2% | -$60.0K | |
| DM | 2024-11-27 | 2024-11-26 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale+OE | $57.99 | -33.5K | 370.4K | -8% | -$1.94M |
| D | 2024-11-27 | 2024-11-26 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | M - OptEx | $29.00 | +30.0K | 403.9K | +8% | +$870.0K |
| 2024-11-18 | 2024-11-15 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $57.70 | -6,500 | 76.8K | -8% | -$375.1K | |
| 2024-11-18 | 2024-11-15 | ANIP | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | F - Tax | $56.58 | -867 | 33.2K | -3% | -$49.1K | |
| 2024-11-14 | 2024-11-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $61.36 | -250 | 56.2K | -0.4% | -$15.3K | |
| 2024-10-15 | 2024-10-14 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $57.19 | -250 | 56.5K | -0.4% | -$14.3K | |
| 2024-09-16 | 2024-09-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $56.82 | -250 | 56.7K | -0.4% | -$14.2K | |
| 2024-09-13 | 2024-09-12 | ANIP | Davis Krista | SVP, Chief HR Off | F - Tax | $56.15 | -1,486 | 50.1K | -3% | -$83.4K | |
| 2024-09-10 | 2024-09-08 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | F - Tax | $60.51 | -3,646 | 373.9K | -1.0% | -$220.6K | |
| 2024-08-14 | 2024-08-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $59.62 | -250 | 57.0K | -0.4% | -$14.9K | |
| I | 2024-07-19 | 2024-07-18 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $62.00 | -2,743 | 632.6K | -0.4% | -$170.1K |
| 2024-07-19 | 2024-07-18 | ANIP | Cook Meredith | SVP, GC, SEC | F - Tax | $61.35 | -1,743 | 57.2K | -3% | -$106.9K | |
| MI | 2024-07-17 | 2024-07-15+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $63.73 | -47.3K | 649.6K | -7% | -$3.01M |
| 2024-07-15 | 2024-07-12 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $64.91 | -250 | 59.0K | -0.4% | -$16.2K | |
| I | 2024-07-02 | 2024-07-01 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $63.44 | -20.0K | 193.2K | -9% | -$1.27M |
| I | 2024-06-24 | 2024-06-21 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $58.90 | -20.0K | 682.6K | -3% | -$1.18M |
| MI | 2024-06-20 | 2024-06-17+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $60.59 | -30.0K | 702.6K | -4% | -$1.82M |
| 2024-06-14 | 2024-06-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $63.80 | -250 | 59.2K | -0.4% | -$15.9K | |
| DM | 2024-06-11 | 2024-06-07 | ANIP | Marken James G. | SVP OPS, PROD DEV | M - OptEx | $52.70 | +12.6K | 123.6K | +11% | +$661.4K |
| D | 2024-06-11 | 2024-06-07 | ANIP | Marken James G. | SVP OPS, PROD DEV | F - Tax | $67.70 | -11.1K | 117.8K | -9% | -$750.6K |
| 2024-06-06 | 2024-06-04 | ANIP | CAREY STEPHEN P. | SVP, CFO | S - Sale | $63.58 | -5,000 | 162.0K | -3% | -$317.9K | |
| 2024-06-06 | 2024-06-05 | ANIP | Gutwerg Ori | SVP, GENERICS | S - Sale | $67.00 | -2,985 | 77.2K | -4% | -$200.0K | |
| I | 2024-06-04 | 2024-06-03 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $64.41 | -20.0K | 213.2K | -9% | -$1.29M |
| 2024-05-23 | 2024-05-21 | ANIP | Leonard Matthew J | Dir | A - Grant | $0.00 | +4,410 | 12.0K | +58% | $0 | |
| 2024-05-23 | 2024-05-21 | ANIP | TANNENBAUM RENEE P | Dir | A - Grant | $0.00 | +4,410 | 22.6K | +24% | $0 | |
| 2024-05-23 | 2024-05-21 | ANIP | Pera Antonio R | Dir | A - Grant | $0.00 | +4,410 | 31.0K | +17% | $0 | |
| 2024-05-23 | 2024-05-21 | ANIP | Walsh Patrick D | Dir | A - Grant | $0.00 | +4,410 | 74.7K | +6% | $0 | |
| 2024-05-23 | 2024-05-21 | ANIP | HAUGHEY THOMAS | Dir | A - Grant | $0.00 | +4,410 | 51.5K | +9% | $0 | |
| 2024-05-23 | 2024-05-21 | ANIP | Thoma Jeanne | Dir | A - Grant | $0.00 | +4,410 | 40.6K | +12% | $0 | |
| 2024-05-22 | 2024-05-21 | ANIP | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $61.61 | -2,000 | 83.3K | -2% | -$123.2K | |
| I | 2024-05-21 | 2024-05-20 | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $61.81 | -12.9K | 732.6K | -2% | -$794.6K |
| MI | 2024-05-17 | 2024-05-15+ | ANIP | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS, Dir | S - Sale | $64.37 | -37.1K | 745.5K | -5% | -$2.39M |
| 2024-05-17 | 2024-05-16 | ANIP | TANNENBAUM RENEE P | Dir | S - Sale | $63.87 | -2,000 | 18.2K | -10% | -$127.7K | |
| 2024-05-16 | 2024-05-14 | ANIP | Lalwani Nikhil | Pres, CEO, Dir | S - Sale | $66.10 | -16.7K | 377.5K | -4% | -$1.10M | |
| 2024-05-13 | 2024-05-13 | ANIP | Cook Meredith | SVP, GC, SEC | S - Sale | $67.69 | -250 | 59.5K | -0.4% | -$16.9K | |
| I | 2024-05-03 | 2024-05-01 | ANIP | Gassert Chad | SVP - CORP. DEV, STRATEGY | S - Sale | $66.62 | -20.0K | 233.2K | -8% | -$1.33M |
Purchase Sale Sale after option exercise All abbreviations